
Work Here?
Work Here?
Work Here?
Kirin is a diversified global group that blends beverages, health science, and biotechnology to offer consumer drinks and health therapeutics. Its fermentation expertise supports functional ingredients like LC-Plasma and Kyowa Kirin develops cancer and rare-disease therapies, leveraging a large global manufacturing and distribution network. The company differentiates itself by combining a biotech drug platform with consumer products and strong ESG practices, including 100% recycled PET packaging and a net-zero footprint, funded by the Kirin Health Innovation Fund. Its goal is to create long-term value by harmonizing nature, science, and industry to improve health and sustainability.
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Consumer Goods
Company Size
201-500
Company Stage
IPO
Headquarters
Tokyo, Japan
Founded
1907
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
PET recycling, chemical recycling, Kirin Holdings, Japan Steel Works, circular economy. Polyestertime September 4, 2026 Revolutionary PET chemical recycling breakthrough delivers massive win for circular economy. Kirin Holdings Company, Limited, through its Packaging Innovation Institute, alongside The Japan Steel Works, Ltd. (JSW), has announced a major leap forward in sustainable materials technology. The companies have successfully demonstrated an industrial-scale alkaline depolymerization technique using JSW's Twin Screw Extruder TEX αIII series. This milestone moves the plastic packaging sector significantly closer to commercial-grade, continuous circular recycling for materials that standard processing methods cannot handle. Overcoming the bottlenecks of traditional plastic recycling. While mechanical recycling remains the primary method for processing used beverage bottles, it faces steep limitations. Mechanical systems generally require highly purified feedstock, mostly limited to clean drink containers. When faced with colored plastics, non-food grade containers, or mixed textile waste, mechanical methods fall short. Conventional chemical recycling methods (such as standard hydrolysis, methanolysis, and glycolysis) can break polymers down to the molecular level to create virgin-quality material. However, these traditional processes historically demand extreme temperatures, high energy consumption, and extended reaction periods. The new joint technology addresses these barriers by utilizing a mechanochemical reaction. By combining chemical agents with mechanical forces - specifically high friction and intense shearing within the twin-screw extruder - the process accelerates bond cleavage without depending solely on thermal energy. PET chemical recycling breakthrough | Metric / Parameter | Demonstration Achievement | | Depolymerization Rate | Exceeds 95% PET breakdown | | Processing Throughput | Stable operation at >= 250 kg/h | | Equipment Used | JSW Twin Screw Extruder TEX αIII Series | | Core Mechanism | Mechanochemical alkaline depolymerization | Scalable performance for commercial-grade processing. The demonstration marked the first Japanese trial of an alkaline depolymerization process using production-scale twin-screw machinery designed to simulate real factory conditions. Key achievements from the trial include: * High Yield Monomer Recovery: The process converted more than 95% of input PET into its constituent building blocks. * Industrial Throughput: Operations maintained continuous stability at processing speeds of 250 kg/h or higher. * Energy-Efficient Design: Lower reaction times and reduced heat requirements significantly diminish operational carbon footprints compared to legacy solvolysis systems. This technological foundation provides critical operational metrics for designing full-scale commercial recycling facilities. PET chemical recycling breakthrough Broader industry context and future implementation. The development comes at a critical time for global waste management strategies. While recent industry reports emphasize that chemical recycling technologies face cost challenges relative to virgin plastic production, high-yield processes exceeding 90% recovery - such as this mechanochemical approach - offer the structural efficiency required to make advanced recycling economically viable. Kirin Group plans to use this technology to advance its target of utilizing 50% recycled resin across its domestic PET bottle portfolio by 2027, as part of its Environmental Vision 2050. Moving forward, Kirin and JSW will evaluate applying this technology across broader PET supply chains, including non-food grade materials and complex waste streams, while collaborating with local governments and industry partners to achieve commercial deployment. PET chemical recycling breakthrough The detailed technical findings of the trial are scheduled for presentation at the 57th Autumn Meeting of the Society of Chemical Engineers, Japan.
Kirin and GenerativeX Transform the Future of Research and Development with AI. Aug 14, 2026, 03:00 ET Introducing a New Model for Co-Creation with Researchers TOKYO, Aug. 14, 2026 /PRNewswire/ - Kirin Holdings Company, Limited (Kirin Holdings) and FDE consulting firm GenerativeX Inc. (GenerativeX) have developed a new research style that incorporates AI agents directly into research activities, with the aim of enhancing researchers' creativity. The initiative was launched in 2026 in select research divisions at Kirin. Through this initiative, Kirin and GenerativeX aim to realize an "AI-native research environment" that supports the entire research process, from hypothesis generation to knowledge sharing, while staying closely aligned with researchers' thinking processes. 1. Background In recent years, advances in generative AI have expanded the use of AI into areas that have traditionally depended on researchers' advanced thinking, such as literature searches and hypothesis generation. At the same time, AI implementation in companies has often remained limited to improving operational efficiency, such as document creation and search. In research and development settings, researchers also face the issue of "fragmented thinking," in which their thought processes are repeatedly interrupted by information searches, searches for past materials, organizing hypotheses, and sharing information. This has made it difficult for researchers to focus on the creative activities that should be their primary focus. 2. Overview In this initiative, Kirin and GenerativeX have built and begun operating a research environment that combines Kirin's vision for research with GenerativeX's AI development capabilities by incorporating AI agents into the flow of research activities. Kirin is responsible for designing the research concept and applying it in research settings, while GenerativeX provides AI technologies and implements the system. The system is currently being used in select research laboratories, with future expansion across the Group also under consideration. Key Features of This Research Style * Design that incorporates AI into the research flow AI is constantly present within the flow of research activities, rather than being called upon by researchers only when needed. * Real-time support that keeps thinking uninterrupted The system provides integrated support for hypothesis generation, information searches, brainstorming, documentation, and knowledge sharing. * A researcher-centered design philosophy AI functions not as a replacement for researchers, but as a collaborative partner that helps bring out their creativity. * From individual knowledge to co-created organizational knowledge Hypotheses, discussions, and exploration histories are accumulated and made available for use across the organization. Development Process The system has been developed in an agile manner while incorporating feedback from researchers. It has been designed by aligning the functions that researchers actually want to use with the possibilities offered by AI technologies. Researchers involved in the development process have recognized the system as a tool suited to their own research activities. Another key feature of this initiative is that AI is being used not merely as a tool for improving operational efficiency, but as a means of supporting the intellectual and creative activity of research itself. The initiative is expected to expand the potential for exploring new hypotheses, promote cross-disciplinary integration, and improve the quality of research. 3. Future Developments Going forward, Kirin and GenerativeX will further enhance the system's functions to better understand each researcher's expertise and research themes, detect signs of emerging issues, propose hypotheses, and promote collaboration among researchers. In the future, the companies aim to create an environment in which AI naturally exists as an integral part of research, becoming a natural and seamless part of the research environment without researchers having to consciously think about using it. 4. About GenerativeX Inc. GenerativeX Inc. is a Forward Deployed Engineer (FDE) consulting firm established in 2023. The company specializes in supporting business transformation for enterprises through the use of AI agents, providing services to major clients in Japan and overseas across industries such as finance, pharmaceuticals, and manufacturing. Headquartered in Marunouchi, Tokyo, GenerativeX also has offices in San Francisco and New York, and is expanding its business globally. The Kirin Group will steadily advance the two pillars of digital utilization set out in "KIRIN Digital Vision 2035"*: "eliminating work that people do not need to do" through productivity improvements, and "accelerating work that creates value together with people" through value creation. Through manufacturing that looks to nature and people, the Kirin Group will bring new joy in "food and health" to more people and contribute to the realization of a fulfilling society. Press Contacts * Kirin Holdings Company, Limited www.kirinholdings.com/en/ Corporate Communication Department Nakano Central Park South, 4-10-2 Nakano, Nakano-ku, Tokyo Media Contact form https://faq.kirin.co.jp/form/kh_10_en.html TEL: +81-3-6837-7028 * GenerativeX Inc. https://gen-x.co.jp/ 27F Marunouchi Building, 2-4-1 Marunouchi, Chiyoda-ku, Tokyo TEL: +81-50-1807-2433 About Kirin Holdings Kirin Holdings Company, Limited is a global company operating across three core business domains spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals. The company traces its roots to Japan Brewery, established in 1885, which later became Kirin Brewery in 1907. Since then, Kirin has expanded its business operations by leveraging fermentation and biotechnology as core strengths. The company entered the pharmaceutical field in the 1980s, which has since grown into a global business. In 2007, the company transitioned to a pure holding company structure as Kirin Holdings, and it is now strengthening its Non-alcoholic Beverages & Health Science domain. Under its long-term vision "Innovate2035!", the Kirin Group is focused on creating value that encourages behavioral change among consumers and patients, creating new lifestyle habits in the areas of food and health. With a unique business portfolio spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals, the Group will further expand group-wide initiatives that support both mental and physical well-being. The Kirin Group will continue to advance innovation through the combined strength of its people and technology, creating both social and economic value as a global leader in CSV*, while pursuing sustainable, long-term growth in corporate value. *Creating Shared Value: combined added value for consumers as well as for society at large. SOURCE GenerativeX
Kirin aims to build North American business platform with Jamieson Wellness acquisition. 06-Aug-2026 Last updated on 06-Aug-2026 at 22:53 GMT The acquisition of Jamieson Wellness represents a significant step in expanding Kirin's Health Science business into North America, said Kirin's COO. (Getty Images) Japan's Kirin Holdings Company has agreed to acquire Jamieson Wellness Inc. for C$2.5 billion (US$1.78 billion), and make the Toronto, Canada-based supplements brand a wholly owned subsidiary. Kirin's long-term vision is to become a global leader in improving consumers' physical and mental well-being and has positioned its Health Science business as a key driver of its medium- to long-term growth, according to a notice to the press about the deal. The company states it is committed to becoming the most trusted health science company across Asia, Oceania, and North America. Having acquired Australian supplement firm Blackmores in 2023 and Japanese cosmetics and supplement company FANCL in 2024 to establish a strong foundation in Asia and Oceania, Kirin turned its attention to North America. Kirin believes Jamieson Wellness is an ideal strategic fit because it brings established brands, strong customer relationships, broad distribution networks, and end-to-end capabilities spanning R&D, manufacturing and sales. These strengths are said to complement Kirin's expertise in fermentation, biotechnology and proprietary health ingredients. Explore related questions. "We are delighted to welcome Jamieson Wellness to the Kirin Group," said Takeshi Minakata, COO of Kirin. "This Transaction represents an important milestone in Kirin's long-term growth strategy and a significant step in expanding our Health Science business into North America, the world's largest vitamins and dietary supplements market." "The acquisition of Jamieson Wellness marks an important step in advancing Kirin's Health Science vision to become a global leader in preventative health," added Alastair Symington, CEO & Managing Director of Blackmores Limited. "It brings trusted brands, strong capabilities in innovation, brand building, manufacturing and go-to-market execution, and a scalable platform in the important North American market. Together, Kirin, Blackmores, FANCL and Jamieson Wellness strengthen a global platform now connecting North America, Asia and Oceania." Jamieson Wellness. Founded in 1922, Jamieson Wellness is Canada's leading supplement company by market share. The company expanded its U.S. presence in 2022 with the acquisition of Nutrawise, parent company of the Youtheory, in a deal worth at least $210 million. Earlier this week Jamieson reported its second quarter results, noting that consolidated revenue increased 17.4% to C$233.8 million. Much of this was driven by its Jamieson brands business, for which revenue increased 18.6% (or C$32.9 million) to C$210.2 million for Q2. Revenue in Canada revenue increased by 5.7% to $91.6 million, while revenue in the U.S. increased by 21.7% on a constant currency basis to C$50.1 million. In China, revenue increased 46.6% on a constant currency basis to C$54.3 million, while other international revenue grew 7.5% on a constant currency basis to C$14.3 million. "Today marks an exciting new chapter for our Company and for our iconic 104-year-old brand," said Mike Pilato, President and CEO of Jamieson Wellness. "From the beginning, it was clear that Kirin recognizes the importance of our heritage, our people, and our Canadian roots. Just as importantly, they are committed to investing in our brands. As a global C$22 billion leader in beverage, natural health, and consumer health, they bring the expertise, reach, and resources to help take our brands to the next level while preserving what has made Jamieson successful for more than a century." The all-cash transaction is subject to several standard closing conditions, including approval by Jamieson Wellness shareholders, court approval, regulatory clearances, and other customary requirements. The deal is expected to close in the fourth quarter of 2026.
Jamieson Wellness to be acquired by Kirin for C$45.75 per Share in cash Represents a 27% premium to the 20-day VWAP of Jamieson Wellness' Shares as of the...
Cognizin(R) Citicoline shows promise for neuromuscular health in new preclinical research. Jul 27, 2026, 08:00 ET Kyowa Hakko will present in vitro findings on the branded ingredient's potential role in neuromuscular junction formation at the American Society for Nutrition's NUTRITION 2026 conference NEW YORK, July 27, 2026 /PRNewswire/ - New preclinical research on Cognizin(R) Citicoline from Kyowa Hakko investigates the branded ingredient's potential to support the formation of the neuromuscular junction (NMJ) - the critical connection between motor neurons and skeletal muscle fibers that governs muscle activation and performance. The findings point to an entirely new dimension of Cognizin's science and its role in the mind-body connection with compelling implications for sports nutrition and healthy aging formulations. Cognizin, which is backed by decades of extensive clinical studies, is now the subject of research in a new area: neuromuscular health. The NMJ is the specialized synapse through which motor neurons signal skeletal muscle to contract - and its integrity is central to muscle strength, coordination, and functional movement. Age-related deterioration of the NMJ is increasingly recognized as a key contributor to muscle weakness and decline in physical performance, making it a high-interest target for both sports nutrition and healthy aging applications. The study, conducted by researchers at the Institute of Health Sciences at Kirin Holdings Company, the parent company of Kyowa Hakko, used an established in vitro neuromuscular cell model to evaluate Cognizin's effects on NMJ formation. Using gene expression analysis and immunofluorescence imaging, researchers assessed key markers involved in NMJ development, including acetylcholine receptor (AChR) clustering, a critical step in the formation of a functional NMJ. "Consumers and manufacturers alike are increasingly demanding more from cognitive health ingredients, expecting to see real science behind the claims," said Karen Todd, vice president of global brand marketing, Kyowa Hakko USA. "Research like this is exactly why Cognizin continues to stand apart. Our ongoing investment in rigorous clinical and preclinical science gives formulators the validated evidence they need to build products consumers can trust - and it opens doors to exciting new application areas we're only beginning to explore. Awareness of the mind-body connection has grown rapidly in recent years, and these results further highlight its importance - and Cognizin's role in it." The full findings will be presented as a poster by lead author Chihiro Ono of Kirin Holdings during the Sports/Performance Nutrition Poster Session at the American Society for Nutrition's conference in July. The session will be held July 27, 2026, from 9:30 to 10:30 a.m. in the Prince George's Exhibition Hall (Lower Atrium Level) at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The poster title is "Citicoline May Strengthen Formation of Neuromuscular Junction by Enhancing Acetylcholine Receptor Clustering in Co-Culture With Neurons and Skeletal Muscle Cells." This research represents the latest chapter in Kyowa Hakko's commitment to advancing the science of Cognizin. For supplement and functional food and beverage manufacturers, it signals an emerging opportunity in sports nutrition and healthy aging formulations backed by a deepening body of evidence. More information about Cognizin is available at Cognizin.com and Kyowa-USA.com. About Kyowa Hakko USA (Kyowa) Kyowa Hakko USA serves as the North and South American headquarters for Kyowa Hakko Bio Co., Ltd., a global pioneer in specialty ingredients within Kirin Holdings' Health Science group. Building on over 75 years of fermentation innovation and Kirin's 100+ year legacy of fermentation excellence, Kyowa delivers premium, science-backed branded ingredients to the nutraceutical, pharmaceutical, functional food, beverage, and wellness industries. The portfolio features branded solutions like Cognizin(R) Citicoline, Setria(R) Glutathione, Pantesin(R) Pantethine, and EYEMUSE(R) Lacticaseibacillus paracasei KW3110. Committed to quality, sustainability, and creating shared value, Kyowa empowers partners to create transformative health solutions, advancing Kirin's vision of improving health and well-being. For more information, visit Kyowa-USA.com. About Cognizin(R) Citicoline Cognizin(R) Citicoline, developed by Kyowa Hakko Bio Co., Ltd., is a clinically patented form of citicoline with over 35 years of research, development, and application experience. Backed by Kyowa's 75-year legacy of biotech innovation and Kirin Holdings' century-long fermentation expertise, Cognizin(R) is produced through state-of-the-art fermentation technology, ensuring superior purity and quality. Clinically tested to support mental energy, focus, attention, and memory, this premium functional ingredient is GRAS, pure, allergen-free, and highly stable. Trusted by global partners in the nutraceutical and wellness sectors, Cognizin(R) advances Kirin's Health Science mission to enhance quality of life through cognitive health solutions. For more information, visit Cognizin.com. SOURCE Kyowa Hakko U.S.A
Find jobs on Simplify and start your career today
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Consumer Goods
Company Size
201-500
Company Stage
IPO
Headquarters
Tokyo, Japan
Founded
1907
Find jobs on Simplify and start your career today